Artificial Eye Market

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed ophthalmology journals, neuroprosthetics literature, and authoritative vision health organizations. Key sources included the US Food & Drug Administration (FDA) Center for Devices and Radiological Health, European Medicines Agency (EMA) Medical Device Coordination Group, National Institutes of Health (NIH) National Eye Institute (NEI), Centers for Disease Control and Prevention (CDC) Vision Health Initiative, World Health Organization (WHO) World Report on Vision, International Agency for the Prevention of Blindness (IAPB), American Academy of Ophthalmology (AAO), American Society of Ocularists (ASO), British Ocular Prosthesis Service (BOPS), National Health Service (NHS) England Specialised Services, PubMed/MEDLINE, ClinicalTrials.gov, and the Cochrane Database of Systematic Reviews. National statistical databases included the US National Center for Health Statistics (NCHS), EU Eurostat Health Database, Japan Ministry of Health Labour and Welfare (MHLW) Statistics Bureau, and national blindness registries from key markets. These sources were utilized to collect procedure statistics for enucleation/evisceration surgeries, regulatory approval data for retinal prosthesis systems (Argus II, Orion, Prima), clinical safety studies for hydroxyapatite and silicone orbital implants, prevalence data for age-related macular degeneration (AMD) and retinitis pigmentosa, demographic trends in vision impairment, and competitive landscape analysis for electronic visual prosthetics and cosmetic ocular prostheses.

To gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, VPs of R&D, heads of regulatory affairs, and commercial directors from companies that manufacture eye implants, eye prosthetics, retinal prostheses, and neuroprosthetics technology were examples of supply-side sources. Board-certified oculoplastic surgeons, vitreoretinal specialists, certified ocularists, directors of ophthalmic prosthetics laboratories, medical device procurement leads from academic medical centers, and healthcare administrators from ambulatory ophthalmic surgery centers and specialty eye institutes were among the demand-side sources. Primary research confirmed product pipeline timelines for subretinal and cortical implants, validated market segmentation between mechanical prosthetics and electronic bionic systems, and collected information on surgical adoption patterns, reimbursement coding for visual prosthetic procedures, and pricing dynamics for custom versus stock shell ocular prostheses.

Primary Respondent Breakdown:

By Designation: C-level Executives (40%), Director Level (25%), Others (35%)

By Region: North America (38%), Europe (25%), Asia-Pacific (25%), Rest of World (12%)

Global market valuation was derived through revenue mapping and surgical procedure volume analysis. The methodology included:

Identification of 30+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America specializing in cosmetic ocular prosthetics, orbital implants (hydroxyapatite, porous polyethylene, silicone), and retinal prosthesis systems

Product mapping across non-integrated ocular prostheses, integrated orbital implants, retinal prosthetic systems (epiretinal, subretinal, and cortical), and electronic bionic eye technologies

Analysis of reported and modeled annual revenues specific to artificial eye portfolios, including Medicare reimbursement data for CPT codes 65091-65175 (enucleation/evisceration procedures) and Category III codes for retinal prosthetic implantation

Coverage of manufacturers representing 65-70% of global market share in 2024, including dominant players in ocular prosthetics and emerging neuroprosthetics developers

Extrapolation using bottom-up (surgical procedure volume × average selling price by country/region) and top-down (manufacturer revenue validation and import/export trade data analysis) approaches to derive segment-specific valuations for mechanical prosthetics, orbital implants, and electronic visual restoration devices